ZT-1a is primarily investigated for its potential therapeutic applications in neurodegenerative diseases, particularly Alzheimer's disease. It functions as a prodrug of huperzine A, which is known for its acetylcholinesterase inhibitory activity. By inhibiting this enzyme, ZT-1a helps increase acetylcholine levels in the brain, which can improve cognitive function and memory in patients with Alzheimer's. Its application is focused on slowing the progression of cognitive decline and enhancing the quality of life for individuals affected by this condition. Research is ongoing to evaluate its efficacy and safety in clinical settings.